Summary

Previous study findings support that overall survival is improved with hormone therapy and conventional-dose radiotherapy in patients with intermediate and high-risk prostate cancer and that biochemical outcomes as well as clinical outcomes were improved with dose-escalated radiotherapy. This article discusses the findings of a phase 3 trial that compared long-term androgen deprivation therapy with short-term androgen deprivation therapy in patients with intermediate and high-risk localized prostate cancer treated with high-dose radiotherapy.